Department of Microbiology, Infection and Immunity Program, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
College of Veterinary Medicine, China Agricultural University, Beijing, China.
J Antimicrob Chemother. 2019 Nov 1;74(11):3190-3198. doi: 10.1093/jac/dkz314.
Until plasmid-mediated mcr-1 was discovered, it was believed that polymyxin resistance in Gram-negative bacteria was mainly mediated by the chromosomally-encoded EptA and ArnT, which modify lipid A with phosphoethanolamine (pEtN) and 4-amino-4-deoxy-l-arabinose (l-Ara4N), respectively. This study aimed to construct a markerless mcr-1 deletion mutant in Klebsiella pneumoniae, validate a reliable reference gene for reverse transcription quantitative PCR (RT-qPCR) and investigate the interactions among mcr-1, arnT and eptA, in response to polymyxin treatments using pharmacokinetics/pharmacodynamics (PK/PD).
An isogenic markerless mcr-1 deletion mutant (II-503Δmcr-1) was generated from a clinical K. pneumoniae II-503 isolate. The efficacy of different polymyxin B dosage regimens was examined using an in vitro one-compartment PK/PD model and polymyxin resistance was assessed using population analysis profiles. The expression of mcr-1, eptA and arnT was examined using RT-qPCR with a reference gene pepQ, and lipid A was profiled using LC-MS. In vivo polymyxin B efficacy was investigated in a mouse thigh infection model.
In K. pneumoniae II-503, mcr-1 was constitutively expressed, irrespective of polymyxin exposure. Against II-503Δmcr-1, an initial bactericidal effect was observed within 4 h with polymyxin B at average steady-state concentrations of 1 and 3 mg/L, mimicking patient PK. However, substantial regrowth and concomitantly increased expression of eptA and arnT were detected. Predominant l-Ara4N-modified lipid A species were detected in II-503Δmcr-1 following polymyxin B treatment.
This is the first study demonstrating a unique markerless deletion of mcr-1 in a clinical polymyxin-resistant K. pneumoniae. The current polymyxin B dosage regimens are suboptimal against K. pneumoniae, regardless of mcr, and can lead to the emergence of resistance.
在发现质粒介导的 mcr-1 之前,人们认为革兰氏阴性菌的多粘菌素耐药性主要是由染色体编码的 EptA 和 ArnT 介导的,它们分别用磷酸乙醇胺(pEtN)和 4-氨基-4-去氧-l-阿拉伯糖(l-Ara4N)修饰脂 A。本研究旨在构建肺炎克雷伯菌无标记 mcr-1 缺失突变体,验证逆转录定量 PCR(RT-qPCR)的可靠参考基因,并利用药代动力学/药效学(PK/PD)研究多粘菌素处理下 mcr-1、arnT 和 eptA 之间的相互作用。
从临床肺炎克雷伯菌 II-503 分离株中生成无标记 mcr-1 缺失突变体(II-503Δmcr-1)。使用体外一室 PK/PD 模型检查不同多粘菌素 B 剂量方案的疗效,并使用群体分析谱评估多粘菌素耐药性。使用 RT-qPCR 检测 mcr-1、eptA 和 arnT 的表达,参考基因 pepQ,并使用 LC-MS 分析脂 A。在小鼠大腿感染模型中研究体内多粘菌素 B 的疗效。
在肺炎克雷伯菌 II-503 中,mcr-1 持续表达,与多粘菌素暴露无关。针对 II-503Δmcr-1,在多粘菌素 B 平均稳态浓度为 1 和 3mg/L 时,在 4 小时内观察到初始杀菌作用,但随后观察到大量再生,并同时检测到 eptA 和 arnT 的表达增加。在多粘菌素 B 处理后,II-503Δmcr-1 中检测到主要的 l-Ara4N 修饰脂 A 物种。
这是第一项在临床多粘菌素耐药肺炎克雷伯菌中证明独特的无标记 mcr-1 缺失的研究。目前的多粘菌素 B 剂量方案对肺炎克雷伯菌均不理想,无论是否存在 mcr,都可能导致耐药性的出现。